Immunofluorescence of a perfusable microvascular network in a vascularized Tissueoid

Human tissue models with a living vasculature.

VJLabs builds vascularized Tissueoids: perfusable, immune-competent human tissue models on a chip, used to study transplant rejection, cancer, and drug response without an animal in the loop.

Explore the research Work with us

What a Tissueoid is

Most organ chips have no blood supply. That is the part we build.

A Tissueoid is a three-dimensional human tissue construct grown around a living, perfusable microvascular network. Because the vessels are real and open, nutrients, drugs, antibodies, and immune cells reach the tissue the way they do in a patient. That single difference is what lets these models sustain perfused culture past seven weeks, take a dose of donor-specific antibody, and report what happens.

Liver Heart wall Lymph node Blood-brain barrier Glioblastoma Adipose

Specimen plates

4Vascularized organ models

49+Days of perfused culture

79Publications

2,875+Citations

Research

Five programs and the five technologies underneath them, from allograft rejection on a chip to cancer vaccine screening in aged immune systems.

Programs and platforms

People

Seven researchers at the bench, thirty alumni now across academia and industry.

The lab

Publications

Every paper, review, preprint, and conference abstract, searchable in one place.

127 records

VJLabs · Terasaki Institute for Biomedical Innovation · Woodland Hills, CA

vjucaud@terasaki.org Scholar ORCID LinkedIn Terasaki Institute

Research programs

Five programs, one vasculature

Each program exists because a specific question could not be answered in a dish or in an animal. They share the same vascularized foundation, which is why immunology, biosensing, and materials work feed directly into one another here.

Liver chip at day 28 — Day 28 of perfusion

Program 01

Organ-on-a-chip and microphysiological systems

The central pillar. We engineer vascularized, perfusable organ models, liver, blood-brain barrier, lymph node, and glioblastoma, that hold together long enough to run a real experiment on.

Why it matters: Conventional models lack vasculature, immune competence, and real-time readouts, which is most of why they fail to predict what a drug does in a person.
How: Scalable thermoplastic fabrication, modular chip architectures, and manufacturing designed for academic, pharmaceutical, and regulatory adoption rather than for a cleanroom.

Platform

Vascularized Tissueoids and the chips that hold them

Perfusable microvascular networks integrated with 3D tissue, so nutrients, drugs, and immune cells move through the construct instead of diffusing into it. The chips themselves are scalable thermoplastic parts with sensor and electrode ports, which is what makes the platform usable by labs without cleanroom access.

4 organ models49+ day cultureNo cleanroom neededSensor-ready

Antibody epitope mapping — Epitope mapping

HLA single antigen bead assay — Single antigen bead assay

Program 02

Transplant immunology and HLA immunobiology

We map how donor-specific HLA antibodies decide the fate of a graft: which mismatches provoke them, which epitopes they see, and what they do to tissue once they arrive.

Why it matters: Antibody-mediated rejection remains the leading cause of long-term graft loss, and predicting which mismatches trigger it is still unsolved.
How: Antibody characterization and epitope mapping, computational donor-recipient matching through the E3 feature software, then rejection replayed on an immunocompetent chip.

Platform

E3, HLA feature engineering software

E3 generates more than 400 molecular features from any donor-recipient HLA mismatch, unifying eplet scores, predicted epitopes, electrostatic and hydrophobicity differences, and antibody-verified epitopes in one framework. Existing tools score immunogenicity with a single metric; E3 exists because a single metric keeps being wrong.

400+ featuresML-readyAntibodies 2024

T cell activation on chip — T cell activation

Program 03

Cancer biology and immunotherapy

Engineered tissue models for cancer vaccine screening, drug resistance, and embolic agent testing, including immune systems that have aged.

Why it matters: Preclinical models rarely capture human immune complexity, least of all in elderly patients, who carry the highest cancer burden and are routinely left out of testing.
How: Lymph node-on-a-chip for vaccine efficacy, glioblastoma-on-a-chip for pericyte-mediated temozolomide resistance, and a vascularized liver tumor model for embolic agents.

Platform

Three cancer platforms on the same vascular base

Lymph node-on-a-chip for vaccine efficacy including aged immune systems, glioblastoma-on-a-chip for pericyte-mediated temozolomide resistance, and a vascularized liver tumor model for embolic agents. All three inherit the perfusable vasculature and immune access of the Tissueoid platform.

3 cancer platformsImmunosenescenceAntigen presentation

Integrated biosensing platform — Biosensing platform

Integrated electrode in a chip — Integrated electrode

Program 04

Biosensors and real-time monitoring

Label-free sensing built into the chip itself, so a tissue can be watched continuously instead of being sacrificed for an endpoint.

Why it matters: Endpoint assays miss the dynamics, and the dynamics are usually where the toxicity signal lives.
How: PC-TIR optical biosensors for antibody secretion and toxicity, screen-printed TEER electrodes for barrier integrity, and reusable electrochemical immunosensors.

Platform

Integrated biosensing

Four sensing modalities embedded in the chip: PC-TIR optical biosensors for antibody secretion and toxicity, screen-printed TEER electrodes for barrier integrity, reusable electrochemical immunosensors, and microfluidic contact-lens sensors for tear biomarkers.

4 modalitiesLabel-freeNon-destructive

Deep eutectic solvent ionogel — DES-based ionogel

Oxygen-generating microparticles — O₂-generating microparticles

Program 05

Biomaterials and tissue engineering

Materials that make the models more faithful, and that occasionally leave the chip entirely and become a treatment.

Why it matters: Matching the mechanics and chemistry of native tissue is a prerequisite for both accurate modeling and direct therapeutic use.
How: Ionogels and peptide hydrogels, oxygen-generating microparticles that downregulate HIF-1α, and natural latex dressings taken as far as a pilot trial in diabetic foot ulcers.

Platform

Engineered materials

Hydrogels and particles that either raise the fidelity of a model or leave the chip and become a therapeutic: DES-based ionogels, peptide and amyloid-mimicking hydrogels, oxygen-generating microparticles that downregulate HIF-1α, and latex-based wound dressings.

5+ material systemsClinical pilotActa Biomater. 2023

VJLabs · Terasaki Institute for Biomedical Innovation · Woodland Hills, CA

vjucaud@terasaki.org Scholar ORCID LinkedIn Terasaki Institute

Publication record

Research output

54Research papers

25Review articles

48Conference abstracts

2,875+Citations

32h-index

Selected work

High-impact and recent papers

2026 · Nature Communications NewZhou K, Kim M, Liu CW, Harbell JW, Mathur AK, Nateras RN, Jucaud V, Dokmeci MR, Shen X, Aqel BA, Wang J, Nguyen MC, Zhu Y. A clinically deployed dual-compartment biochemical monitoring platform for human liver perfusion. doi: 10.1038/s41467-026-74799-y.
2026 · Chemical Engineering JournalCabral TO, Ebrahimi A, Bagheri A, Khorsandi D, Dokmeci MR, Jucaud V, Pourkargar DB. A digital twin framework for predictive modeling of liver-on-a-chip system dynamics using limited experimental data. doi: 10.1016/j.cej.2026.177046.
2026 · Advanced MaterialsSalih ARC, Peirsman A, Khorsandi D, Ferrao R, Ferreira L, Kamaraj M, John JV, Baquerizo A, Jucaud V. Liver Tissueoid on-a-Chip Modeling Liver Regeneration and Allograft Rejection.
2025 · ACS SensorsTang RC, et al. Rapid Point-of-Care Inflammatory Cytokine Monitoring during Normothermic Liver Perfusion via a Multiplexed Paper-Based Vertical Flow Assay.
2025 · Lab on a ChipMaity S, Hassani Najafabadi A, et al. Lymph node paracortex-inspired on-a-chip recapitulating immunosenescence.
2025 · Biosensors and BioelectronicsKhorsandi D, Yang JW, et al. Real-Time and Label-Free Monitoring of Monoclonal Antibody Secretion Rates Using a PC-TIR Biosensor.
2025 · BiofabricationNguyen HT, et al. Embolization-on-a-chip: Novel Vascularized Liver Tumor Model for Evaluation of Cellular and Cytokine Response to Embolic Agents.
2025 · Acta BiomaterialiaMaity S, Jewell C, et al. Deciphering pericyte-induced temozolomide resistance in glioblastoma with a 3D microphysiological system.
2024 · SmallYang JW, Khorsandi D, et al. Liver-on-a-Chip Integrated with Label-Free Optical Biosensors for Rapid and Continuous Monitoring of Drug-Induced Toxicity.
2020 · Scientific ReportsKawakita S, Beaumont JL, Jucaud V, Everly MJ. Personalized prediction of delayed graft function for recipients of deceased donor kidney transplants.
2019 · HepatologyJucaud V, Shaked A, et al. Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial.
2026 · Nature Communications NewZhou K, Kim M, Liu CW, Harbell JW, Mathur AK, Nateras RN, Jucaud V, Dokmeci MR, Shen X, Aqel BA, Wang J, Nguyen MC, Zhu Y. A clinically deployed dual-compartment biochemical monitoring platform for human liver perfusion. doi: 10.1038/s41467-026-74799-y.
2026 · Chemical Engineering JournalCabral TO, Ebrahimi A, Bagheri A, Khorsandi D, Dokmeci MR, Jucaud V, Pourkargar DB. A digital twin framework for predictive modeling of liver-on-a-chip system dynamics using limited experimental data. doi: 10.1016/j.cej.2026.177046.
2026 · Advanced MaterialsSalih ARC, Peirsman A, Khorsandi D, Ferrao R, Ferreira L, Kamaraj M, John JV, Baquerizo A, Jucaud V. Liver Tissueoid on-a-Chip Modeling Liver Regeneration and Allograft Rejection.
2025 · ACS SensorsTang RC, et al. Rapid Point-of-Care Inflammatory Cytokine Monitoring during Normothermic Liver Perfusion via a Multiplexed Paper-Based Vertical Flow Assay.
2025 · Lab on a ChipMaity S, Hassani Najafabadi A, et al. Lymph node paracortex-inspired on-a-chip recapitulating immunosenescence.
2025 · Biosensors and BioelectronicsKhorsandi D, Yang JW, et al. Real-Time and Label-Free Monitoring of Monoclonal Antibody Secretion Rates Using a PC-TIR Biosensor.
2025 · BiofabricationNguyen HT, et al. Embolization-on-a-chip: Novel Vascularized Liver Tumor Model for Evaluation of Cellular and Cytokine Response to Embolic Agents.
2025 · Acta BiomaterialiaMaity S, Jewell C, et al. Deciphering pericyte-induced temozolomide resistance in glioblastoma with a 3D microphysiological system.
2024 · SmallYang JW, Khorsandi D, et al. Liver-on-a-Chip Integrated with Label-Free Optical Biosensors for Rapid and Continuous Monitoring of Drug-Induced Toxicity.
2020 · Scientific ReportsKawakita S, Beaumont JL, Jucaud V, Everly MJ. Personalized prediction of delayed graft function for recipients of deceased donor kidney transplants.
2019 · HepatologyJucaud V, Shaked A, et al. Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial.

Full record

Every paper, review, and abstract

2026 Zhou K, Kim M, Liu CW, Harbell JW, Mathur AK, Nateras RN, Jucaud V, Dokmeci MR, Shen X, Aqel BA, Wang J, Nguyen MC, Zhu Y. A clinically deployed dual-compartment biochemical monitoring platform for human liver perfusion. Nature Communications. 2026; 17(1):5627. doi:10.1038/s41467-026-74799-y
2026 Cabral TO, Ebrahimi A, Bagheri A, Khorsandi D, Dokmeci MR, Jucaud V, Pourkargar DB. A digital twin framework for predictive modeling of liver-on-a-chip system dynamics using limited experimental data. Chemical Engineering Journal. 2026. 177046. doi:10.1016/j.cej.2026.177046
2026 Salih ARC, Peirsman A, Khorsandi D, Ferrao R, Ferreira L, Kamaraj M, John JV, Baquerizo A, Jucaud V. Liver Tissueoid on-a-Chip Modeling Liver Regeneration and Allograft Rejection. Advanced Materials. e21178. doi:10.1002/adma.202521178
2025 Tang RC, et al. Rapid Point-of-Care Inflammatory Cytokine Monitoring during Normothermic Liver Perfusion via a Multiplexed Paper-Based Vertical Flow Assay. ACS Sensors. doi:10.1021/acssensors.5c01902
2025 Maity S, Hassani Najafabadi A, et al. Lymph node paracortex-inspired on-a-chip recapitulating immunosenescence: a cancer vaccine immunogenicity and antitumoral efficacy screening platform. Lab on a Chip. doi:10.1039/D5LC00533G
2025 Hernandez AL, et al. Continuous Optical Biosensing of IL-8 Cancer Biomarker Using a Multimodal Platform. Bioengineering. 12(10):1115. doi:10.3390/bioengineering12101115
2025 Khorsandi D, Yang JW, et al. Real-Time and Label-Free Monitoring of Monoclonal Antibody Secretion Rates Using a PC-TIR Biosensor. Biosensors and Bioelectronics. 117979. doi:10.1016/j.bios.2025.117979
2025 Nguyen HT, et al. Embolization-on-a-chip: Novel Vascularized Liver Tumor Model for Evaluation of Cellular and Cytokine Response to Embolic Agents. Biofabrication. doi:10.1088/1758-5090/adfbc3
2025 Maity S, Jewell C, et al. Deciphering pericyte-induced temozolomide resistance in glioblastoma with a 3D microphysiological system mimicking the biomechanical properties of brain tissue. Acta Biomaterialia. doi:10.1016/j.actbio.2025.05.038
2025 Joshi A, et al. Filamented Light (FLight) Biofabrication of Aligned Fibrillar Structures to Direct 3D Cell Organization Within Microgels. Small. 2500261. doi:10.1002/smll.202500261
2025 de Barros NR, et al. Novel highly flexible collagen-loaded latex dressing to treat diabetic foot ulcer: A pilot clinical trial. Int J Biol Macromol. 308:142615. doi:10.1016/j.ijbiomac.2025.142615
2025 Mathes TG, et al. Lipopeptide Hydrogel Possesses Adjuvant-Like Properties for the Delivery of the GPC-3 Peptide-derived Antigen. Adv. Funct. Mater. 2413870. doi:10.1002/adfm.202413870
2025 Maity S, Hassani Najafabadi A, Kawakita S, Khorsandi D, Yilgor C, Jewell C, Mohaghegh M, Dokmeci MR, Khademhosseini A, Jucaud V. Modeling Immunosenescence on-a-chip: a platform for cancer vaccine efficacy assessment. bioRxiv. 2025; 05.14.654059. doi:10.1101/2025.05.14.654059 Peer-reviewed version in Lab on a Chip.
2025 Nguyen HT, Tirpáková Z, Peirsman A, et al., Jucaud V. Embolization-on-a-chip: Novel Vascularized Liver Tumor Model for Evaluation of Cellular and Cytokine Response to Embolic Agents. bioRxiv. 2025; 03.30.646225. doi:10.1101/2025.03.30.646225 Peer-reviewed version in Biofabrication.
2024 Kamaraj M, et al. Granular Porous Nanofibrous Microspheres Enhance Cellular Infiltration for Diabetic Wound Healing. ACS Nano. doi:10.1021/acsnano.4c10044
2024 Mohaghegh N, et al. Simvastatin-Loaded Polymeric Nanoparticles: Targeting Inflammatory Macrophages for Local Adipose Tissue Browning in Obesity Treatment. ACS Nano. doi:10.1021/acsnano.4c10742
2024 Yang JW, Khorsandi D, et al. Liver-on-a-Chip Integrated with Label-Free Optical Biosensors for Rapid and Continuous Monitoring of Drug-Induced Toxicity. Small. 2403560. doi:10.1002/smll.202403560
2024 Costabeber G, et al. Additive manufacturing of polylactic acid scaffolds dip-coated with polycaprolactone for bone tissue engineering. Materials Today Communications. 40:109646. doi:10.1016/j.mtcomm.2024.109646
2024 Mathes TG, et al. Effects of amyloid-β-mimicking peptide hydrogel matrix on neuronal progenitor cell phenotype. Acta Biomaterialia. doi:10.1016/j.actbio.2024.05.020
2024 Rezaei Z, et al. Noninvasive and Continuous Monitoring of On-Chip Stem Cell Osteogenesis Using a Reusable Electrochemical Immunobiosensor. ACS Sens. doi:10.1021/acssensors.3c02165
2024 Jiang C, et al. A Role of Tissue-Resident Memory T Cells on Melanoma Prognosis. iScience. 27(3):109277. doi:10.1016/j.isci.2024.109277
2024 Maity S, Jewell C, Yilgor C, et al., Jucaud V. Microphysiological system modeling pericyte-induced temozolomide resistance in glioblastoma. bioRxiv. 2024; 07.16.603611. doi:10.1101/2024.07.16.603611 Peer-reviewed version in Acta Biomaterialia.
2023 Herculano RD, et al. Amphotericin B-loaded natural latex dressing for treating Candida albicans wound infections. J Control Release. 365:744-758. doi:10.1016/j.jconrel.2023.12.010
2023 Kawakita S, et al. Rapid integration of screen-printed electrodes into thermoplastic organ-on-a-chip devices for real-time monitoring of TEER. Biomedical Microdevices. 25:37. doi:10.1007/s10544-023-00669-9
2023 Abdalla G, et al. Eco-sustainable coatings based on chitosan, pectin, and lemon essential oil nanoemulsion. Int J Biol Macromol. 249:126016. doi:10.1016/j.ijbiomac.2023.126016
2023 Herculano RD, et al. Aloe vera-loaded natural rubber latex dressing as a potential complementary treatment for psoriasis. Int J Biol Macromol. 242:124779. doi:10.1016/j.ijbiomac.2023.124779
2023 de Souza Silva FK, et al. Biocompatible anti-aging face mask prepared with curcumin and natural rubber. Int J Biol Macromol. 124778. doi:10.1016/j.ijbiomac.2023.124778
2023 Wilson N, et al. Ixazomib for Desensitization (IXADES) in Highly Sensitized Kidney Transplant Candidates. Kidney360. doi:10.34067/KID.0000000000000113
2023 Mandal K, et al. Oxygen-generating microparticles downregulate HIF-1α expression, increase cardiac contractility, and mitigate ischemic injury. Acta Biomaterialia. 159:211-225. doi:10.1016/j.actbio.2023.01.030
2023 Ge G, et al. Deep Eutectic Solvents-Based Ionogels with Ultrafast Gelation and High Adhesion. Adv. Funct. Mater. 33(9):2207388. doi:10.1002/adfm.202207388
2023 Mecwan MM, et al. Thermoresponsive shear-thinning hydrogel hemostats for minimally invasive treatment of external hemorrhages. Biomater Sci. 11(3):949-963. doi:10.1039/d2bm01559e
2022 Zhu Y, et al. A Microfluidic Contact Lens to Address Contact Lens-Induced Dry Eye. Small. 2207017. doi:10.1002/smll.202207017
2022 de Paiva MB, et al. Latex-collagen membrane: an alternative treatment for tibial bone defects. J Mater Sci. doi:10.1007/s10853-022-08009-7
2022 Li S, et al. Microchambers Containing Contact Lens for the Noninvasive Detection of Tear Exosomes. Adv Funct Mater. 2206620. doi:10.1002/adfm.202206620
2022 Zhu Y, et al. Epidermis-Inspired Wearable Piezoresistive Pressure Sensors Using Reduced Graphene Oxide. Small Methods. 6(1):2100900. doi:10.1002/smtd.202100900
2022 Lee J, et al. pH-Responsive doxorubicin delivery using shear-thinning biomaterials for localized melanoma treatment. Nanoscale. 14(2):350-60. doi:10.1039/D1NR05738C
2021 Zhu Y, et al. Ultrathin-shell epitaxial Ag@Au core-shell nanowires for high-performance devices. Nano Research. 14(11):4294-303. doi:10.1007/s12274-021-3718-z
2020 Kawakita S, Beaumont JL, Jucaud V, Everly MJ. Personalized prediction of delayed graft function for recipients of deceased donor kidney transplants with machine learning. Scientific Reports. 10(1):18409. doi:10.1038/s41598-020-75473-z
2020 Jucaud V, et al. Validation and cross-reactivity pattern assessment of monoclonal antibodies for donor-specific IgG antibody subclasses. J Immunol Methods. 486:112847. doi:10.1016/j.jim.2020.112847
2020 Chen Y, et al. Microengineered poly(HEMA) hydrogels for wearable contact lens biosensing. Lab on a Chip. 20(22):4205-14. doi:10.1039/D0LC00446D
2019 Jucaud V, Shaked A, et al. Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients. Hepatology. 69(3):1273-86. doi:10.1002/hep.30281
2017 Ravindranath MH, Jucaud V, Ferrone S. Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay. J Immunol Methods. 450:73-80. doi:10.1016/j.jim.2017.07.016
2017 Ravindranath MH, Jucaud V, et al. Nature and Clonality of the Fluoresceinated Secondary Antibody in Luminex Multiplex Bead Assays. J Immunol. 198(11):4524-38. doi:10.4049/jimmunol.1700050
2017 Jucaud V, Ravindranath MH, Terasaki PI. Conformational Variants of the Individual HLA-I Antigens on Luminex Single Antigen Beads. Transplantation. 101(4):764-77. doi:10.1097/TP.0000000000001420
2017 Jucaud V. The Immunogenicity of HLA Class II Mismatches. J Immunol Res. 2017:2748614. doi:10.1155/2017/2748614
2017 Hilali FE, Jucaud V, et al. Characterization of the Anti-HLA Class I and II IgG Antibodies in Moroccan IVIg. Int J Immunology. 5(4):53-65. doi:10.11648/j.iji.20170504.11
2016 Ravindranath MH, Jucaud V, et al. Significance of the differences in the prevalence of anti-HLA antibodies in matched pairs of mother's and cord blood. Immunology Letters. 170:68-79. doi:10.1016/j.imlet.2015.11.016
2016 Jucaud V, et al. Serum antibodies to HLA-E, HLA-F and HLA-G in patients with SLE during disease flares. Clin Exp Immunol. 183(3):326-40. doi:10.1111/cei.12724
2015 Ravindranath MH, et al. The Monospecificity of Novel Anti-HLA-E Monoclonal Antibodies. Monoclon Antib Immunodiagn Immunother. 34(3):135-53. doi:10.1089/mab.2014.0096
2015 Ravindranath MH, et al. IgG purified from human sera mirrors IVIg HLA reactivity and recognizes one's own HLA types. Clin Exp Immunol. 179(2):309-28. doi:10.1111/cei.12450
2014 Zhu D, et al. Suppression of allo-HLA antibodies secreted by B memory cells: IVIg versus a monoclonal anti-HLA-E IgG. Clin Exp Immunol. 177(2):464-77. doi:10.1111/cei.12307
2014 Sasaki T, et al. Gastric cancer progression may involve a shift in HLA-E profile. Int J Cancer. 134(7):1558-70. doi:10.1002/ijc.28484
2014 Ravindranath MH, et al. Suppression of blastogenesis and proliferation of activated CD4+ T cells: IVIg versus novel anti-HLA-E monoclonal antibodies. Clin Exp Immunol. 178(1):154-77. doi:10.1111/cei.12391
2013 Ravindranath MH, et al. Therapeutic preparations of IVIg contain naturally occurring anti-HLA-E antibodies that react with HLA-Ia alleles. Blood. 121(11):2013-28. doi:10.1182/blood-2012-08-447771

2025 Mohaghegh N, et al. Immunoengineering strategies using nanoparticles for obesity treatment. Nano Research. doi:10.26599/NR.2025.94907707
2025 Burd BS, et al. Can the insects Galleria mellonella and Tenebrio molitor be the future of plastic biodegradation? Science of The Total Environment. 969:178879. doi:10.1016/j.scitotenv.2025.178879
2024 Maity S, et al. Recent Developments in Glioblastoma-On-A-Chip for Advanced Drug Screening Applications. Small. e2405511. doi:10.1002/smll.202405511
2024 Khorsandi D, et al. Lab-on-a-chip: Unit Operations to Scale-up Strategies. In: Lab-on-a-chip Devices for Advanced Biomedicines. RSC. doi:10.1039/9781837673476
2024 Jucaud V. Allogeneic HLA Humoral Immunogenicity and the Prediction of Donor-Specific HLA Antibody Development. Antibodies. 13(3):61. doi:10.3390/antib13030061
2024 Marques PAC, et al. Natural rubber latex-based biomaterials for drug delivery and regenerative medicine. Int J Biol Macromol. 131666. doi:10.1016/j.ijbiomac.2024.131666
2024 Khorsandi D, et al. Patient-Derived Organoids as Therapy Screening Platforms in Cancer Patients. Adv. Healthcare Mater. e2302331. doi:10.1002/adhm.202302331
2024 Zare EN, et al. Biomedical applications of engineered heparin-based materials. Bioactive Materials. 31:87-118. doi:10.1016/j.bioactmat.2023.08.002
2023 Mohaghegh N, et al. Injectable Hydrogels for Personalized Cancer Immunotherapies. Acta Biomaterialia. 172:67-91. doi:10.1016/j.actbio.2023.10.002
2023 Falcone N, et al. Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery. Adv. Healthcare Mater. 2301096. doi:10.1002/adhm.202301096
2023 Karamikamkar S, et al. Aerogel-Based Biomaterials for Biomedical Applications. Adv. Sci. 2204681. doi:10.1002/advs.202204681
2023 Peirsman A, et al. Vascularized adipose tissue engineering: moving towards soft tissue reconstruction. Biofabrication. 15(3). doi:10.1088/1758-5090/acd7a5
2023 Nguyen HT, et al. Engineered Vasculature for Cancer Research and Regenerative Medicine. Micromachines. 14(5):978. doi:10.3390/mi14050978
2022 Mou L, et al. Integrated biosensors for monitoring microphysiological systems. Lab on a Chip. 24(8):2358-2359. doi:10.1039/D2LC00262K
2022 Kawakita S, et al. Organ-On-A-Chip Models of the Blood–Brain Barrier: Recent Advances and Future Prospects. Small. 18(39):e2201401. doi:10.1002/smll.202201401
2022 Zhu Y, et al. Lab-on-a-Contact Lens: Recent Advances and Future Opportunities. Advanced Materials. 34(24):e2108389. doi:10.1002/adma.202108389
2021 Zhu Y, et al. State of the art in integrated biosensors for organ-on-a-chip applications. Curr Opin Biomed Eng. 19:100309. doi:10.1016/j.cobme.2021.100309
2021 Zhu Y, et al. Recent Advances in Bioinspired Hydrogels. ACS Biomater Sci Eng. 9(5):2048-69. doi:10.1021/acsbiomaterials.1c00741
2021 Nasrollahi F, et al. Micro and Nanoscale Technologies for Diagnosis of Viral Infections. Small. 17(45):2100692. doi:10.1002/smll.202100692
2021 Ma X, et al. Smart Contact Lenses for Biosensing Applications. Adv Intell Syst. 3(5):2000263. doi:10.1002/aisy.202000263
2020 Zhou X, et al. Engineering Antiviral Vaccines. ACS Nano. 14(10):12370-89. doi:10.1021/acsnano.0c06109
2017 El-Awar N, Jucaud V, Nguyen A. HLA Epitopes: The Targets of Monoclonal and Alloantibodies Defined. J Immunol Res. 2017:3406230. doi:10.1155/2017/3406230
2015 Ravindranath M, Jucaud V, Terasaki P. Immunobiology of Allograft HLA in the New Microenvironment. SOJ Immunol. 3(4):1-19. doi:10.15226/2372-0948/3/4/00135
2015 Jucaud V, Ravindranath M, Terasaki P. Immunobiology of HLA class-Ib molecules in transplantation. SOJ Immunol. 3(4):1-15. doi:10.15226/2372-0948/3/4/00137
2013 Ravindranath MH, et al. Anti-HLA-E monoclonal antibodies reacting with HLA-Ia and Ib alleles like IVIg as potential IVIg-immunomimetics. Clin Transpl. 293-305. PMID:25095521

48 of 58 abstracts are listed. Ten 2026 presentations (ATW, TTS, ATC, and the xenotransplantation congress) are pending citation details.

2025 Salih ARC, Baquerizo A, Jucaud V. Vascularized Liver Tissueoid-on-a-Chip: An In Vitro Model for Studying Allograft Rejection. Am J Transplant. 25(8), S60. Oral presentation. World Transplant Congress 2025 (San Francisco).
2025 Jiang C, et al. Machine Learning-Based Risk Prediction of Allograft Rejection within One-Year Post-Transplant for Kidney Transplant Patients. Am J Transplant. 25(8), S67. Oral presentation. World Transplant Congress 2025 (San Francisco).
2025 Baquerizo A, Jucaud V, Keshavarz A, Markmann J. Xenogeneic Profiling of Human Plasma Protein Abundance Following Pig Hepatocyte Exposure during Bioartificial Liver Treatments. Am J Transplant. 25(8), S558. Poster presentation. World Transplant Congress 2025 (San Francisco).
2024 Hassani Najafabadi A, et al. Simvastatin-Loaded Polymeric Nanoparticles for Obesity Treatment. Oral. BMES 2024 (Baltimore).
2024 Nguyen HT, et al. Novel Vascularized Liver Tumor Model For Evaluation Of Embolic Agents. Oral. BMES 2024 (Baltimore).
2024 Falcone N, et al. Lipopeptide-based hydrogel for delivery of the GPC-3 peptide-derived antigen. Poster. BMES 2024 (Baltimore).
2024 Yang JW, et al. Liver-on-a-Chip Integrated with Label-free Optical Biosensors for Drug-induced Toxicity. Oral. BMES 2024 (Baltimore).
2024 Khorsandi D, et al. Real-time and Label-free Monitoring of Monoclonal Antibody Secretion Rate Using a PC-TIR Sensor. Oral. BMES 2024 (Baltimore).
2024 Salih ARC, et al. Patient-Derived Glioblastoma Models for Personalized Medicine: TMZ Chemoresistance Screening. Poster. BMES 2024 (Baltimore).
2024 Baquerizo A, Jucaud V. Differential expression of human xenoantibodies to wt and GalT-KO pig endothelial cells. Transplantation. 108(9S). Oral. ITS 2024 (Istanbul).
2024 Kawakita S, et al. Computational immuno-profiling and prediction of antibody-mediated rejection. Transplantation. 108(9S). Poster. ITS 2024 (Virtual).
2024 Jucaud V. Advances in bioengineering research for transplantation. Invited speaker. Expert Talk IMIN 2024.
2024 Jucaud V. The Three Pillars of Organs-On-a-Chip Technologies. Invited speaker. 11th Annual 3Rs Symposium 2024.
2024 Jucaud V. Manufacturing Tomorrow's Therapeutics: Innovations in Bioprinting. Invited panelist. RAPID + TCT 2024 (Los Angeles).
2024 Kawakita S, et al. Transcriptomic signatures of antibody-mediated rejection in kidney transplant recipients. Poster. ATC 2024 (Philadelphia).
2023 Jucaud V. Brain-on-a-chip Platforms For Drug Discovery and Off Target Toxicity Studies. Invited speaker. World Congress SBMT 2023 (Los Angeles).
2023 Baquerizo A, Jucaud V. Analysis of human anti-porcine immune response. Transplantation. 107(10S2), S127. Oral. IPITA-IXA-CTRMA 2023 (San Diego).
2023 Nguyen HT, et al. Vascularized liver tumor model for vessel embolic agents testing. Oral. ESB 2023 (Davos).
2022 Jucaud V. Recapitulating the Human Body On a Chip: Progress to Date. Invited speaker. JSNN Nanoimpacts 2022 (Greensboro).
2022 Jucaud V. Microscale Sensors and Systems for Tissue Engineering. Invited speaker. JSNN Nanoimpacts 2022 (Greensboro).
2022 Mandal K, et al. Oxygen-generating microparticles increase cardiac contractility. Oral. BMES 2022 (San Antonio).
2022 Mandal K, et al. Improving cardiomyocyte contractility beating by introducing oxygen releasing microparticles. Oral. SFB 2022 (Baltimore).
2020 Jucaud V, et al. Do we predict mismatches that induce de novo DSA or those that do not? Transplantation. 104(S3), S49-S50. Oral. ITS 2020.
2020 Jucaud V, et al. Molecular features of HLA mismatches as predictors of de novo DSA development. Oral. ATC 2020.
2020 Jucaud V, et al. HLA mismatch immunogenicity: are we predicting mismatches that induce de novo DSA or those that do not? Poster. ATC 2020.
2020 Jucaud V, et al. Is the epitope mismatch load enough to identify HLA-DQ mismatches with a low risk for de novo DSA development? Poster. ATC 2020.
2020 Jucaud V, et al. Preformed anti-HLA donor-specific antibodies immunological risk assessment: the importance of HLA antibody locus-specificity. Poster. ATC 2020.
2019 Jucaud V, et al. Mismatched epitope and de novo DSA development: BENEFIT and BENEFIT-EXT Analysis. Am J Transplant. 19:384. Oral. ATC 2019 (Boston).
2019 Jucaud V, et al. Impact of HLA-DR matching on HLA-DQ matching status and de novo DSA. Am J Transplant. 19:699-700. Poster. ATC 2019 (Boston).
2019 Kawakita S, et al. A Prognostic Biomarker for De Novo DSA in Kidney Transplant Recipients. Am J Transplant. 19:638-39. Poster. ATC 2019 (Boston).
2019 Jucaud V, et al. Mismatched antibody epitopes and the development of HLA-DQ de novo DSA during immunosuppression withdrawal in liver transplant recipients. Am J Transplant. 19:1166-67. Poster. ATC 2019 (Boston).
2019 Babu A, et al. Endothelial cells do not regulate expression of CD46, CD55 and CD59 in the presence of anti-HLA class I and II antibodies. Am J Transplant. 19:899-900. Poster. ATC 2019 (Boston).
2019 Babu A, et al. Differential regulation of phosphokinases by anti-HLA class I and II antibodies. Am J Transplant. 19:620. Poster. ATC 2019 (Boston).
2019 Jucaud V, et al. Incompatibilités des épitopes et apparition des anticorps spécifiques du donneur (de novo DSA). Une analyse des études BENEFIT et BENEFIT-EXT chez les patients transplantés rénaux. Poster (présenté par Blancho G). Société Francophone de Transplantation 2019 (Bordeaux).
2018 Jucaud V, et al. Development of post-transplant DSA in adult liver transplant patients from the ITN A-WISH trial. Transplantation. 102:S203. Oral. ITS 2018 (Madrid).
2018 Jucaud V, et al. Development of post-transplant DSA following immunosuppression withdrawal in liver transplant recipients. Am J Transplant. 18:472-473. Oral. ATC 2018 (Seattle).
2018 Dadhania D, et al. Epitope load does not predict development of de novo antibodies to HLA in patients with BK virus nephropathy. Hum Immunol. 79:23. Oral. ASHI 2018 (Baltimore).
2018 Jucaud V, et al. The relative immunogenicity of HLA mismatches in adult liver transplant patients from the ITN A-WISH trial. Transplantation. 102:S623. Poster. ITS 2018 (Madrid).
2018 Jucaud V, et al. Not all HLA mismatches are equal: determining the de novo DSA induction capacity of HLA mismatches. Am J Transplant. 18:443-444. Oral. ATC 2018 (Seattle).
2018 Jucaud V, et al. The relative immunogenicity of HLA mismatches in adult liver transplant recipients. Am J Transplant. 18:626. Poster. ATC 2018 (Seattle).
2018 Everly MJ, et al. All DQ DSA may not be equal: comparing outcomes between de novo DQ DSA specificities. Am J Transplant. 18:443. Oral. ATC 2018 (Seattle).
2018 Everly MJ, Jucaud V, et al. Immunogenic HLA mismatches and evidence that belatacept may be the first therapy able to prevent DQ de novo DSA. Am J Transplant. 18:780. Poster. ATC 2018 (Seattle).
2018 Jucaud V, et al. Determining the relative immunogenicity of HLA mismatches: BENEFIT and BENEFIT-EXT analysis. Am J Transplant. 18:289-290. Oral. ATC 2018 (Seattle).
2016 Jucaud V, Ravindranath MH, Terasaki PI. Evidence for structural variants within an individual HLA-I molecule coated on Luminex single antigen beads. Transplantation. 100(7):S377-78. Oral. ITS 2016 (Hong Kong).
2016 Ravindranath MH, Jucaud V, et al. Importance of the nature and binding specificity of the secondary antibody used in Luminex single antigen bead assays. Transplantation. 100(7):S375-76. Oral. ITS 2016 (Hong Kong).
2016 Jucaud V, Ravindranath MH, Terasaki PI. Structural variants within an individual HLA-I molecule on single antigen beads: impact on organ allocation and de novo DSA monitoring. Am J Transplant. 16:514-15. Poster. ATC 2016 (Boston).
2015 Ravindranath MH, Terasaki PI, Maehara C, Jucaud V. Should current IVIg preparations containing high titers of anti-HLA-I/-II IgG be used for lowering anti-HLA IgG in sensitized patients and allograft recipients? Am J Transplant. 15. Poster. ATC 2015 (Philadelphia).
2014 Jucaud V, et al. Antibody levels of HLA-E, HLA-F, HLA-G and β2-microglobulin correlate with disease activity of systemic lupus erythematosus by SLEDAI and BILAG-2004. Poster. International Congress on Autoimmunity 2014 (Nice).